Overview and Specificity of Psilocybin Use in the Treatment of Mental Disorders: A Scientometric Analysis
Maria Helha Fernandes-Nascimento, Karine Viana-Ferreira, André Brooking Negrão
Psychedelic Medicine January 21, 2025 DOI: 10.1089/psymed.2024.0031 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Bibliometric analysis Randomized Peer reviewed |
|---|---|
| Population | Publications on psilocybin and mental disorders |
| Topics | Psilocybin |
| Keywords | Hallucinogen |
| Citations | 2 |
| Key points | Psilocybin research publications have grown exponentially, and meta-analyses indicate its efficacy for depression, anxiety, and substance use disorders. |
Abstract
Background: Psilocybin is a natural alkaloid with therapeutic potential in the treatment of different mental disorders. Bibliometric information on its use is still scattered in the literature.
Objective: To investigate the temporal and bibliometric patterns of publications and the specificity of psilocybin in the treatment of mental disorders.
Method: Performed a bibliometric analysis using VOSviewer software. Documents from the period 1963 to 2023 were retrieved from the Scopus database. The search string comprised terms related to psilocybin and mental disorders. An exponential regression was performed to investigate the number of publications over time. The specificity was evaluated based on a manual analysis of the clinical trials’ findings carried out with individuals diagnosed with mental disorders.
Results: We identified 853 eligible publications. An exponential regression analysis revealed an increase in the number of publications over time, with significant growth between 2016 and 2023 (52%). Publications cover countries on five continents, but are predominantly from nations with a high Human Development Index, such as the United States and the United Kingdom. Depression was the most prominent term in keyword analysis. Meta-analyses have indicated the efficacy of psilocybin in the treatment of different mental disorders (depression, anxiety, and substance use disorders).
Conclusion: The global academic panorama shows the growing recognition of psilocybin as a promising alternative in psychiatric treatment, highlighting the need for randomized clinical trials to ensure its safe and effective use.
Citations in the library
Cited by 2
- Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review. Current microbiology July 15, 2025
- A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder Current Treatment Options in Psychiatry December 26, 2025
Cites 26
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 21 more in the library